NO20054714L - Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom - Google Patents

Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom

Info

Publication number
NO20054714L
NO20054714L NO20054714A NO20054714A NO20054714L NO 20054714 L NO20054714 L NO 20054714L NO 20054714 A NO20054714 A NO 20054714A NO 20054714 A NO20054714 A NO 20054714A NO 20054714 L NO20054714 L NO 20054714L
Authority
NO
Norway
Prior art keywords
disease
procedures
preventing
cognitive impairments
alzheimer
Prior art date
Application number
NO20054714A
Other languages
English (en)
Other versions
NO20054714D0 (no
Inventor
Mark Steven Shearman
Mervyn Turner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20054714D0 publication Critical patent/NO20054714D0/no
Publication of NO20054714L publication Critical patent/NO20054714L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet anvendelse av en forbindelse av formel I eller et farmasøytisk akseptabelt salt derav, for fremstilling av et medikament for behandling av aldersrelatert kognitivt forfall eller mild kognitiv svekkelse, i særdeleshet for å forhindre eller forsinke starten av Alzheimers sykdom.
NO20054714A 2003-03-14 2005-10-13 Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom NO20054714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45458903P 2003-03-14 2003-03-14
PCT/GB2004/000983 WO2004080459A1 (en) 2003-03-14 2004-03-08 Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease

Publications (2)

Publication Number Publication Date
NO20054714D0 NO20054714D0 (no) 2005-10-13
NO20054714L true NO20054714L (no) 2005-11-16

Family

ID=32990914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054714A NO20054714L (no) 2003-03-14 2005-10-13 Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom

Country Status (13)

Country Link
US (1) US20060241133A1 (no)
EP (1) EP1605940A1 (no)
JP (1) JP2006520371A (no)
KR (1) KR20050109990A (no)
CN (1) CN1794992A (no)
AU (1) AU2004218871A1 (no)
BR (1) BRPI0408295A (no)
CA (1) CA2518886A1 (no)
IS (1) IS8004A (no)
MX (1) MXPA05009850A (no)
NO (1) NO20054714L (no)
RU (1) RU2005131845A (no)
WO (1) WO2004080459A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
MY148558A (en) * 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
LU92126B1 (fr) * 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
AU5486396A (en) * 1995-04-19 1996-11-07 Merck & Co., Inc. Process for the preparation of spiroindolines
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
EP0900086A4 (en) * 1996-05-07 2000-01-12 Merck & Co Inc IMPROVING THE SLEEP BY MEANS OF A SUBSTANCE PROMOTING THE SECRETION OF GROWTH HORMONES
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
EP1109572A4 (en) * 1998-09-03 2004-11-24 Neuronz Ltd NEUROPROTECTION
CA2395996A1 (en) * 1999-12-28 2001-07-05 Kaken Pharmaceutical Co., Ltd. Neuroprotective drug
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues

Also Published As

Publication number Publication date
NO20054714D0 (no) 2005-10-13
AU2004218871A1 (en) 2004-09-23
EP1605940A1 (en) 2005-12-21
CN1794992A (zh) 2006-06-28
KR20050109990A (ko) 2005-11-22
IS8004A (is) 2005-08-29
JP2006520371A (ja) 2006-09-07
RU2005131845A (ru) 2006-02-10
BRPI0408295A (pt) 2006-03-07
US20060241133A1 (en) 2006-10-26
CA2518886A1 (en) 2004-09-23
WO2004080459A1 (en) 2004-09-23
MXPA05009850A (es) 2005-12-06

Similar Documents

Publication Publication Date Title
NO20054714L (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
GB0225475D0 (en) Therapeutic agents
GB0005251D0 (en) Therapeutic compounds
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
GB0223038D0 (en) Therapeutic compounds
EA200400881A1 (ru) Азаарилпиперазины
SE0202462D0 (sv) Novel use
GB0318447D0 (en) Therapeutic agents
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
JO2282B1 (en) Oxazole derivatives
GB0225474D0 (en) Therapeutic agents
GB0112348D0 (en) Compounds
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
WO2004029031A3 (en) Therapeutic piperazine compounds
SE0202429D0 (sv) Novel Compounds
EA200401114A2 (ru) Замещённые гидроксиэтиламины
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
NZ790364A (en) Compounds and compositions for use in treating skin disorders
GB0130677D0 (en) Medicaments and novel compounds
MY133527A (en) Isoquinoline derivatives
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser